Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Malte Selch, Larsen"'
Publikováno v:
Clinical Pharmacology in Drug Development. 11:910-921
Tralokinumab is the first biologic therapy for moderate-to-severe atopic dermatitis (AD) that specifically neutralizes interleukin-13 activity, a key driver of AD signs and symptoms. Tralokinumab is a human immunoglobulin G4 monoclonal antibody admin
Autor:
Juliana C. Small, Shannon M. Zintner, Malte Selch Larsen, Bo Wiinberg, Mattias Häger, Paris Margaritis, K. M. Lövgren, Maj Petersen, Mads Kjelgaard-Hansen
Publikováno v:
J Thromb Haemost
Background Prophylactic replacement therapy in hemophilia A (HA) patients does not adequately prevent bleeds and arthropathic complications. A more refined understanding of the relationship between coagulation factor VIII (FVIII) levels and bleeding
Autor:
Mads Kreilgaard, Bo Wiinberg, Annemarie T. Kristensen, Ulrika S. H. Simonsson, Mads Kjelgaard-Hansen, Shannon M. Zintner, Malte Selch Larsen, Paris Margaritis, Rasmus Vestergaard Juul
Publikováno v:
Haemophilia. 26:164-172
Introduction Monitoring of clinical effectiveness of bypassing agents in haemophilia patients is hampered by the lack of validated laboratory assays. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) have been evaluated for predicti
Autor:
Frederik Rode, Malte Selch Larsen, Isabell Vargas Christensen, Mette Loftager, Hanne Mørck Nielsen, Mads Kreilgaard
Publikováno v:
Journal of Thrombosis and Haemostasis. 17:964-974
Essentials Knowledge of the interplay between FVIII and VWF pharmacokinetics (PK) is lacking. We characterized the capacity-limited PK of FVIII and VWF. The PK model described the PK of FVIII and VWF over a broad range of rFVIII doses. High-dose rFVI
Autor:
Ulrika S. H. Simonsson, Mads Kreilgaard, Malte Selch Larsen, Annemarie T. Kristensen, Rasmus Vestergaard Juul
Publikováno v:
European Journal of Pharmaceutical Sciences. 123:531-538
Historically, clinical trials of haemophilia with inhibitors (HwI) have been challenged by the small patient population. New approaches to clinical trial methodology and statistical modelling could potentially be used for study optimization. The aim
Autor:
Rada M. Savic, Gordon Munro, Mads Kreilgaard, René Holm, Malte Selch Larsen, Ron J. Keizer, Arne Mørk
Publikováno v:
Pharmaceutical Research. 33:1133-1143
Gabapentin displays non-linear drug disposition, which complicates dosing for optimal therapeutic effect. Thus, the current study was performed to elucidate the pharmacokinetic/pharmacodynamic (PKPD) relationship of gabapentin’s effect on mechanica
Autor:
Malte Selch Larsen, Mads Kreilgaard, Annemarie T. Kristensen, Henrik Agersø, Rasmus Vestergaard Juul, Ulrika S. H. Simonsson, Andreas Velsing Groth, Tom Knudsen
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 115
Various experimental animal models are used in haemophilia research, however, little is known about how well the different species predict pharmacokinetic (PK) profiles in haemophilia patients. The aim of the current study was to describe the plasma
Autor:
Malte Selch Larsen, Martha Kampp Nøhr, René Holm, Carsten Uhd Nielsen, Sidsel Frølund, Mats Garmer, Mads Kreilgaard
Publikováno v:
Pharmaceutical Research. 32:898-909
Gabapentin exhibits saturable absorption kinetics, however, it remains unclear which transporters that are involved in the intestinal transport of gabapentin. Thus, the aim of the current study was to explore the mechanistic influence of transporters